Sun Pharma to Acquire US-Based Organon in $11.75 Billion Deal, Its Biggest Overseas Acquisition
The acquisition is strategically important because Organon brings a strong global portfolio in women’s health, biosimilars and established medicines. The New Jersey-headquartered company operates in more than 140 countries and has over 70 products across its portfolio. Organon was formed as a spin-off from Merck, known as MSD outside the United States and Canada, in 2021.